Plastic Surgery Department, Southwest Hospital, Army Military Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Plastic Surgery Department, State Key Laboratory of Trauma, Burns and Combined Injury, Southwest Hospital, Army Military Medical University, Chongqing, 400038, China.
Aesthetic Plast Surg. 2020 Jun;44(3):962-970. doi: 10.1007/s00266-020-01621-5. Epub 2020 Mar 12.
The combination of finasteride and topical minoxidil has been used for treating patients with androgenetic alopecia (AGA). However, whether combining these two medications results in greater efficacy than monotherapy is a question worth exploring.
This meta-analysis aims to determine the efficacy and safety of combined treatment of finasteride and topical minoxidil.
A comprehensive search of the Embase, PubMed, and the Cochrane Library databases was performed. Data were extracted and analyzed according to predefined clinical endpoints.
Five randomized controlled trials (RCTs) were included in our meta-analysis. All studies compared combined therapy with minoxidil, but only 2 RCTs compared combined therapy with finasteride. Compared with minoxidil or finasteride alone, the combined group had a significantly higher global photographic evaluation score (P < 0.00001), more patients with marked improvement (P < 0.001), and fewer patients with deterioration or no change (P < 0.001). There was no significant difference between the combined group and minoxidil- or finasteride-only groups in the number of patients with moderate and mild improvements, hair density change, or adverse events.
In patients with AGA, the combination treatment of finasteride and topical minoxidil has better therapeutic efficacy than and similar safety as monotherapy. However, the best concentration of combination treatment requires further studies with sound methodological quality.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
非那雄胺联合外用米诺地尔已被用于治疗雄激素性脱发(AGA)患者。然而,联合使用这两种药物是否比单一疗法更有效是一个值得探讨的问题。
本荟萃分析旨在确定非那雄胺联合外用米诺地尔治疗的疗效和安全性。
对 Embase、PubMed 和 Cochrane Library 数据库进行全面检索。根据预先设定的临床终点提取和分析数据。
本荟萃分析纳入了 5 项随机对照试验(RCT)。所有研究均比较了联合治疗与米诺地尔的疗效,只有 2 项 RCT 比较了联合治疗与非那雄胺的疗效。与米诺地尔或非那雄胺单药治疗相比,联合组的总体照片评估评分显著更高(P < 0.00001),显著改善的患者更多(P < 0.001),恶化或无变化的患者更少(P < 0.001)。联合组与米诺地尔或非那雄胺单药组的中度和轻度改善患者数量、头发密度变化或不良反应发生率无显著差异。
在 AGA 患者中,非那雄胺联合外用米诺地尔治疗的疗效优于单一疗法,且安全性相当。然而,联合治疗的最佳浓度需要进一步研究,以确保方法学质量。
证据等级 III:本刊要求作者为每篇文章指定证据等级。有关这些循证医学等级的完整描述,请参考目录或在线作者指南 www.springer.com/00266。